


A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

## Washington State Transactions by Industry

Transactions (Millions)



### News highlights:

- Juno Therapeutics acquired Stage Cell Therapeutics, a German company devoted to the engineering and manufacturing of cell therapies.
- Theraclone Sciences struck a deal to hunt down therapeutic antibodies for the lethal ebolavirus using its I-Star screening platform.
- Kineta expanded into an additional 6,000 square feet in a new building in South Lake Union. Administrative operations moved to the new space so that lab operations could grow in the original building.
- Seattle Genetics teamed up with Cambridge, MA-based Unum Therapeutics in a \$645 million immuno-oncology deal. Seattle Genetics will pay \$25M as an upfront payment and making a \$5M investment in Unum and another \$615M in milestones is also in play for up to three antibody-coupled T-cell receptor programs.
- The Fred Hutch recruited Nicole Robinson as the new vice president of industry relations and business development.

### Deal highlights:

- Mirabilis Medical \$2.9M (Debt)
- Adaptive Biotechnologies \$195M (Venture Equity)
- Theraclone Sciences \$3.08M (Venture Equity)
- Cyrus Biotechnology \$850K (Debt)
- InDemand Interpreting \$4M (Venture Equity)
- Cytodyn \$3.3M (Debt)
- KPI Therapeutics \$27K (Equity)
- Ventec Life Systems \$8.2M (Equity)
- BioViva USA \$250K (Equity)
- C-SATS \$2.5M (Venture Equity)
- Magnolia Medical \$6.2M (Venture Equity)
- Carena \$13.3M (Partnership)
- **May 2015 total: \$217,600,530**
- **2015 running total: \$1,066,719,912**

Prepared by Yesenia Green, PhD, on June 5, 2015


\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.

May 2015


## SBIR/STTR Funding Overview

The following information was compiled from the [NIH SBIR/STTR Award Data Table #216](#). We selected Massachusetts and California because they have robust life science sectors and Michigan because it has an active state SBIR/STTR Program. Although the number of STTR applications has increased, the number of awards to Washington State has remained steady.

**All SBIR Phases**  
Success Rates\*



**All STTR Phases**  
Success Rates\*



\*Success rates are defined as the percentage of reviewed grant applications that receive funding.

### Total SBIR Awards, 2014

State	All SBIR Phases		Phase I		Phase II	
	Total Funding	# of Awards	Total Funding	# of Awards	Total Funding	# of Awards
WASHINGTON	\$8,330,568	28	\$5,095,881	23	\$3,009,687	4
MICHIGAN	\$4,980,258	12	\$1,657,386	8	\$3,107,848	3
MASSACHUSETTS	\$37,207,258	102	\$14,907,434	67	\$20,420,888	27
CALIFORNIA	\$78,494,218	237	\$39,743,017	175	\$34,585,391	45
NATIONAL	\$332,235,272	952	\$144,793,079	652	\$170,387,226	229

### Total STTR Awards, 2014


State	All SBIR Phases		Phase I		Phase II	
	Total Funding	# of Awards	Total Funding	# of Awards	Total Funding	# of Awards
WASHINGTON	\$1,042,817	3	\$421,737	2	\$621,080	1
MICHIGAN	\$761,296	4	\$761,296	4	\$0	0
MASSACHUSETTS	\$7,116,766	19	\$3,333,808	14	\$3,782,958	5
CALIFORNIA	\$9,035,623	34	\$6,253,859	27	\$2,165,055	4
NATIONAL	\$59,093,147	202	\$35,828,877	160	\$22,182,184	37

NIH SBIR/STTR

Did you know?

### Washington Life Sciences, Did You Know? Crossing the Cascade Curtain

The Cascade Curtain is no barrier to Washington state's scientific legacy! [Irwin Rose](#) shared the Nobel Prize in Chemistry in 2004 for his research in immune defense and proteins. He spent his first undergraduate year at Washington State University and received the WSU Regents' Distinguished Alumnus Award in 2005.



\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.

## Washington-based Life Science Transactions 2014-2015

Date	Company	Type	Amount
01/07/14	Cardiac Dimensions	Debt	\$367,000
01/08/14	Seattle Genetics	Partnership	\$25,000,000
01/13/14	Juno Therapeutics	Series A extension	\$25,000,000
01/13/14	ActX	Seed equity	\$1,900,000
01/14/14	NuvoMed	Undisclosed	\$535,000
01/21/14	Seattle Genetics	Partnership	\$9,000,000
02/04/14	Acucela	IPO (Japan)	\$162,000,000
02/12/14	Cardiac Dimensions	debt	\$456,000
02/12/14	Nativis	Venture Equity	\$9,160,000
02/25/14	Cheetah Medical	Venture Equity	\$9,000,000
03/05/14	Immunexpress	Venture Equity	\$6,000,000
03/14/14	Kineta	Venture Equity	undisclosed
03/14/14	Nortis	Undisclosed	\$1,200,000
03/17/14	CadenceMD	Debt	\$55,000
03/20/14	Cardiac Dimensions	Debt	\$380,000
03/25/14	Clarity Health	Venture Equity	\$836,000
03/25/14	BioLife Solutions	IPO	\$15,400,000
03/25/14	FlexMinder	Series A	\$1,200,000
03/26/14	KinDex Pharmaceuticals	Series A	\$5,000,000
04/07/14	Adaptive Biotechnologies	Series C&D	\$105,000,000
04/09/14	Oricula Therapeutics	Seed equity	\$122,000
04/10/14	Tissue Regeneration Systems	Venture Equity	\$1,500,000
04/14/14	JeNu Biosciences	Debt	\$1,480,000
04/14/14	Etubics	Seed equity	\$4,400,000
04/16/14	Cardiac Dimensions	Venture Equity	\$20,000,000
04/18/14	X2 Biosystems	Debt	\$2,510,000
04/24/14	Juno Therapeutics	Series A extension	\$31,000,000
04/29/14	Integrated Diagnostics	Series B and Debt	\$47,250,000
05/08/14	Alder Biopharmaceuticals	IPO	\$80,000,000
05/13/14	Stratos Genomics	Series B	\$10,000,000
05/14/14	PharmaIN	Venture Equity	\$1,500,000
05/15/14	AVM Biotechnology	Series B	\$1,500,000
05/16/14	Kineta	Equity	\$1,627,498
06/06/14	Cheetah Medical	Venture Equity	\$5,000,000
06/06/14	NanoString Technologies	Partnership	\$5,750,000
06/15/14	Cardiac Insight	Partnership	\$7,000,000
07/01/14	Pregenen	Acquired	\$20,000,000
07/11/14	Nortis	Venture Equity	\$1,000,000
07/15/14	Valant Medical Solutions	Venture Equity	\$11,000,000
07/18/14	ActX	Venture Equity	\$750,000
07/21/14	Nativis	Undisclosed	\$2,319,000
07/25/14	Immune Design	IPO	\$60,000,000
07/29/14	Accelerator Corporation	Venture Equity	\$51,100,000
07/30/14	Theraclone Sciences	Partnership	undisclosed
07/30/14	Jintronix	Debt	\$772,500
08/04/14	Juno Therapeutics	Series B	\$134,000,000
08/07/14	Immune Design	License	\$168,000,000
08/11/14	Alpine BioSciences	Acquisition	\$27,000,000
08/15/14	Carena	Debt	\$1,995,000
08/21/14	Immunosoft	Venture Equity	\$2,300,000

\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.

# Washington Life Science Report



09/02/14	Clarity Health	Venture Equity	\$1,059,352
09/10/14	Seattle Genetics	Licensing	\$11,000,000
09/23/14	VentiRx Pharmaceuticals	Venture Equity	\$19,300,000
09/26/14	Array Health	Venture Equity	\$13,000,000
10/07/14	Cardiac Dimensions	Venture Equity	\$8,500,000
10/08/14	Blaze BioScience	NCI SBIR Phase II Funding	\$1,500,000
10/09/14	Mirador Biomedical	Acquired	undisclosed
10/27/14	Limeade	Venture Equity	\$25,000,000
11/19/14	IDRI	Contract	\$3,600,000
11/21/14	Aortica	Series A	\$7,000,000
12/09/14	Allen Institute for Cell Science	Paul Allen Donation	\$100,000,000
12/19/14	Juno Therapeutics	IPO	\$264,600,000
12/30/14	Oncogenex	Venture Equity	\$27,000,000
12/30/14	Cerevast Therapeutics	Venture Equity	\$10,000,000
<b>2014 Total</b>			<b>\$1,569,924,350</b>

Date	Company	Type	Amount
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000
01/22/15	Adaptive Biotechnologies	Equity	\$93,750,000
01/28/15	Vesiflo	Convertible note	\$650,000
01/30/15	MalarVx, Inc	Equity	\$110,000
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000
02/13/15	Stasys Medical	Series A	\$160,000
02/18/15	StratoScientific	Venture Equity	\$550,000
02/23/15	Dendreon	Acquisition	\$495,000,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000
03/15/15	Medical Mirror Systems	Equity	\$250,000
03/19/15	Nortis	Venture Equity	\$408,845
03/20/15	Healthentic	Series C	\$3,750,000
03/20/15	StratoScientific	Venture Equity	\$150,000
03/25/15	Cadence Biomedical	Equity	\$959,578
04/08/15	NuvoMed	Equity	\$390,637
04/10/15	Cardeas Pharma	Series B	\$3,500,000
04/13/15	Carena	Debt	\$500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000
04/23/15	Deep Domain	Venture Equity	\$30,000
04/24/15	Mpirica Health	Series A	\$1,600,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000
05/06/15	Adaptive Biotechnologies	Venture Equity	\$195,000,000
05/06/15	Theraclone Sciences	Venture Equity	\$3,080,000
05/06/15	Cyrus Biotechnology	Debt	\$850,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000
05/14/15	Cytodyn	Debt	\$3,281,050
05/19/15	KPI Therapeutics	Equity	\$27,000
05/21/15	Ventec Life Systems	Equity	\$8,192,480
05/27/15	BioViva USA	Equity	\$250,000
06/02/15	C-SATS	Venture Equity	\$2,500,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322
06/04/15	Carena	Partnership	\$13,300,000
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000
<b>2015 Running Total as of 06/05/15</b>			<b>\$1,066,719,912</b>

\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.